Old Web
English
Sign In
Acemap
>
Paper
>
A phase 1 dosing study of bevacizumab for ROP: 12-month ocular outcomes
A phase 1 dosing study of bevacizumab for ROP: 12-month ocular outcomes
2018
Eric R. Crouch
David K. Wallace
Raymond T. Kraker
Michael X. Repka
Janine E. Collinge
Michael E. Gray
Paul G. Steinkuller
Don L. Bremer
Keywords:
Bevacizumab
Surgery
Intensive care medicine
Dosing
Diabetes mellitus
Medicine
Internal medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]